United Therapeutics(US:UTHR) ZACKSยท2024-05-30 14:55Group 1: Zacks Style Scores Overview - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks with the best chances of outperforming the market over the next 30 days [2][3] - Each stock is assigned a rating from A to F, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] Group 2: Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Group 3: Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Group 4: Momentum Score - The Momentum Score helps investors capitalize on price trends, using factors like one-week price change and monthly earnings estimate changes [4] Group 5: VGM Score - The VGM Score combines Value, Growth, and Momentum Scores to provide a comprehensive indicator for stock selection [5] Group 6: Zacks Rank - The Zacks Rank is a proprietary stock-rating model based on earnings estimate revisions, helping investors build successful portfolios [6] - Stocks rated 1 (Strong Buy) have produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7] Group 7: Stock to Watch - United Therapeutics (UTHR) - United Therapeutics Corporation markets four medicines for pulmonary arterial hypertension, including Remodulin, Orenitram, Tyvaso, and Adcirca [10] - UTHR is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of A, having increased 4.9% over the past four weeks [11] - The Zacks Consensus Estimate for UTHR's fiscal 2024 earnings has risen by $1.16 to $24.62 per share, with an average earnings surprise of 12.4% [11][12]